Oncology Adjuvants Market size is expected to reach USD 4 billion by the end of 2036, growing at a CAGR of 5% during the forecast period i.e., 2024-2036. In the year 2023, industry size of oncology adjuvants was USD 1 billion. A major driver for the global market is the increasing incidence of cancer worldwide. As cancer cases proceed to extend, there's a developing request for successful treatment choices, counting adjuvant treatments that can progress persistent results. Considering WHO's factsheet of February 2022, cancer is one of the driving causes of passing, which killed 10 million deaths in 2020, which is one in six deaths.
Complementary adjuvant treatments have become necessary due to the development of innovative and targeted treatments for different types of cancer. In order to enhance their effectiveness and reduce the risk of recurrence, adjuvant medicinal products are used for primary cancer treatment such as surgery, chemotherapy or radiation therapy. Technological advances in drug delivery systems and formulations are also contributing to the market for Oncology Adjuvants. The potential applications of adjuvants have been expanded by the development of targeted drug delivery systems, immunotherapies, and personalized medicine approaches, which have led to increased market demand.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~5% |
|
Base Year Market Size |
~USD 1 billion |
|
Forecast Year Market Size |
~USD 4 billion |
|
Regional Scope |
|
Indication (Sarcoma, Breast Cancer, Colorectal Cancer, Glioblastoma, Prostate Cancer, Lung Cancer, Ovarian Cancer)
Based on indication, the breast cancer segment is predicted to account for 15% share of the global oncology adjuvants market during the forecast period. The growth of this segment can be attributed to the back of increasing prevalence of breast cancer. As per data generated by WHO, in 2020 around 2.3 million women were diagnosed with breast cancer and 685000 individuals lost their life due to this disease. Breast cancer is one of the foremost common sorts of cancer among ladies all-inclusive, and adjuvant treatments play a vital part in overseeing and treating this malady. Adjuvant treatments in breast cancer are utilized after essential treatment, regularly including surgery to evacuate the tumor. The essential objective of adjuvant treatments in breast cancer is to decrease the hazard of cancer repeat and make strides in long-term survival rates. They are managed to target any remaining cancer cells that will not have been killed by surgery and to anticipate the spread of cancer cells to other parts of the body.
End User (Cancer Research Institute, Cancer Hospitals)
In terms of end user, the cancer hospital segment is predicted to account for 80% share of the global oncology adjuvants market by 2036. Market growth is expected to be driven by increasing demand for cancer hospitals around the world. Lung cancer, colon cancer, prostate cancer, breast cancer, and other forms of gynecological cancers are treated in cancer hospitals. It helps to reduce the recurrence of cancer by treating it effectively. By increasing the effectiveness of primary therapy, cancer hospitals have been increasingly using this approach in improving patient outcomes. In order to improve the overall effectiveness of therapy, it is used. Market growth is also expected to be driven by increased funding for cancer research and an increase in the incidence of cancer around the world. The product is typically a drug that is used along with primary cancer treatments such as radiation therapy, surgery, and chemotherapy. In the coming years, these factors are expected to accelerate market developments.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
Indication |
|
|
End User |
|
North American Market Forecasts
The market in the North America region is predicted to hold the highest CAGR of 35% during the prediction period. Factors such as the rising incidence of cancer, a large patient population, good healthcare facilities, and an emphasis on research and development can be attributed to this growth. In 2019, in the United States, it was reported that there were 1,752,735 new cancer cases recorded, and 599,589 individuals died from cancer reported as of the Center for Disease Control and Prevention statistics of June 2022. In addition, significant advances in healthcare technology and innovation have been made in North America. There is an established pharmaceutical and biotechnology sector in the region that contributes to developing new adjuvants and targeted treatments. The market growth is also supported by the adoption of advanced drug delivery systems and personalized approaches to medicine.
APAC Market Statistics
The market in the Asia Pacific region is set to grow notably during the time period between 2024- 2036. This growth can be attributed to an increase in per capita healthcare expenditure due to higher quality. The market opportunities are expected to be expanded by increasing R&D initiatives and increased demand for cancer treatments in this area. Moreover, the market's growth is supported by a growing number of cancer hospitals and an increased acceptance of new technology.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?